Infinis Nutrition launched ‘Metabolic Peptide 461,’ a weight management supplement the brand says focuses on GLP-1 support and post-meal blood sugar balance. It pairs 400mg of ‘DygloFit’ with ‘Pep2Dia,’ giving the product a more blood sugar-focused angle than the appetite-led approach of the brand’s earlier supplement.
‘Pep2Dia’ appears at a 1.4g dose, which makes it the headline ingredient in the four-capsule serving. ‘DygloFit’ comes from dichrostachys glomerata fruit pods, and the formula also includes other branded components, though the main claim focuses on meal-time glucose response rather than general weight loss.
Infinis Nutrition shows how a $74.99 supplement can tie weight management to a specific metabolic use case while broadening the category from broad appetite control to blood sugar support for buyers already watching meal response.
Image Credit: Stack3d
Why This Trend Is Growing
- GLP-1 Support Supplements
- Ingredient-led formulas are expanding beyond appetite messaging into metabolic support positioning tied to consumer familiarity with GLP-1 pathways.
- Post-meal Glucose Management
- Meal-time blood sugar response is becoming a more specific wellness use case for premium supplements targeting weight-conscious shoppers.
- Branded Bioactive Stacks
- Clinically framed combinations of named ingredients create differentiation in a crowded supplement market where perceived efficacy drives premium pricing.
Industries Being Reshaped
- Nutritional Supplements
- The category is shifting toward condition-specific metabolic products that blend weight management, glucose balance, and branded ingredient credibility.
- Weight Management
- A broader range of non-prescription products is redefining weight control around metabolic markers rather than simple appetite suppression.
- Functional Ingredients
- Demand for recognizable bioactives such as peptides and botanical extracts supports new ingredient platforms built around measurable post-meal outcomes.
